Serum paraoxonase-1 enzyme activities and oxidative stress levels in patients with esophageal squamous cell carcinoma

Redox Report

Volumn 19, Issue 5, 2014, Pages 199-205

  Sehitogullari, Abidin ^a   Aslan, Mehmet ^b   Sayir, Fuat ^b   Kahraman, Ali ^a   Demir, Halit ^b  

^a Van Education and Research Hospital   (Turkey)

^b YUZUNCU YIL UNIVERSITY   (Turkey)

Author keywords

Esophageal squamous cell carcinoma; Glutathione peroxidase; Malondialdehyde; PON1 activity; Superoxide dismutase

Indexed keywords

ANTINEOPLASTIC AGENT; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; GLUTATHIONE REDUCTASE; SUPEROXIDE DISMUTASE; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKER; CARBOXYLESTERASE; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; PON1 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; SPECTROPHOTOMETRY; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; ESOPHAGUS TUMOR; FOLLOW UP; LIPID PEROXIDATION; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA;

ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CARBOXYLIC ESTER HYDROLASES; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HUMANS; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; PROGNOSIS; PROSPECTIVE STUDIES; SUPEROXIDE DISMUTASE;

EID: 84903772367     PISSN: 13510002     EISSN: 17432928     Source Type: Journal    
DOI: 10.1179/1351000214Y.0000000091     Document Type: Article

References (58)

1. Kuwano H, Nakajima M, Miyazaki T, Kato H. Distinctive clinicopathological characteristics in esophageal squamous cell carcinoma. Ann Thorac Cardiovasc Surg 2003;9:6-13.
2. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative disease of ageing. Proc Natl Acad Sci USA 1993;90:7915-22.
3. Ames BN, Gold LS, Willet WC. The causes and prevention of cancer. Proc Natl Acad Sci 1995;92:5258-65.
4. Giovannucci E, WilletWC. Dietary factors of colon cancer. Ann Med 1994;26:443-52.
5. Batcioglu K, Mehmet N, Ozturk IC, Yilmaz M, Aydogdu N, Erguvan R, et al. Lipid peroxidation and antioxidant status in stomach cancer. Cancer Investigation 2006;24:18-21.
6. Nishikawa M. Reactive oxygen species in tumor metastasis. Cancer Lett 2008;266:53-9.
7. Nielsen F, Mikkelsen BB, Nielsen JB, Andersen HR, Grandjean P. Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. Clin Chem 1997;43:1209-14.
8. Niki E. Lipid peroxidation products as oxidative stress biomarkers. Biofactors 2008;34:171-80.
9. Janssen AM, Bosman CB, van Duijn W, Oostendorp-van de Ruit MM, Kubben FJ, Griffioen G, et al. Superoxide dismutases in gastric and esophageal cancer and the prognostic impact in gastric cancer. Clin Cancer Res 2000;6(8):3183-92.
10. Levy RD, Oosthuizen MM, Degiannis E, Greyling D, Hatzitheofilou C. Glutathione-linked enzymes in benign and malignant oesophageal tissue. Br J Cancer 1999;80:32-7.
11. Halliwell B, Gutteridge JMC. Biologically relevant metal iondependent hydroxyl radical generation. FEBS Lett 1992;307: 108-12.
12. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high-density lipoprotein against lowdensity lipoprotein oxidative modification. FEBS Lett 1998; 423:57-60.
13. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999;19:330-5.
14. Elkiran ET, Mar N, Aygen B, Gursu F, Karaoglu A, Koca S. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer 2007;7:48-55.
15. Malik UU, Siddiqui IA, Hashim Z, Zarina S. Measurement of serum paraoxonase activity and MDA concentrations in patients suffering with oral squamous cell carcinoma. Clin Chim Acta 2014;430:38-42.
16. Eroglu M, Yilmaz N, Yalcinkaya S, Ay N, Aydin O, Sezer C. Enhanced HDL-cholesterol-associated anti-oxidant PON-1 activity in prostate cancer patients. Kaohsiung J Med Sci 2013; 29(7):368-73.
17. Aydin O, Yacinkaya S, Eren E, Ergin M, Eroglu M, Yilmaz N. Diminished arylesterase enzyme activity and total thiol levels in bladder cancer patients. Clin Lab 2013;59(11-12):1231-7.
18. Akçay MN, Yilmaz I, Polat MF, Akçay G. Serum paraoxonase levels in gastric cancer. Hepatogastroenterology 2003;50:273-5.
19. Akçay MN, Polat MF, Yilmaz I, Akçay G. Serum paraoxonase levels in pancreatic cancer. Hepatogastroenterology 2003;50: 225-7.
20. Kodydkova J, Vavrova L, Stankova B, Macasek J, Krechler T, Zak A. Antioxidant status and oxidative stress markers in pancreatic cancer and chronic pancreatitis. Pancreas 2013;42(4): 614-21.
21. Bulbuller N, Eren E, Ellidag HY, Oner OZ, Sezer C, Aydin O, et al. Diagnostic value of thiols, paraoxonase 1, arylesterase and oxidative balance in colorectal cancer in human. Neoplasma 2013;60(4):419-24.
22. Cayir K, Bilici M, Tekin SB, Kara F, Turkyilmaz A, Yildinm A. Serum paraoxonase and arylesterase activities in esophageal cancer: a controlled study. Eur J Gen Med 2010;7(4):398-403.
23. Jass JR, Sobin LH, Watanabe H. The World Health Organization's histologic classification of gastrointestinal tumors. A commentary on the second edition. Cancer 1990; 66(10):2162-7
24. EckersonHW, Wyte MC, La Du BN. The human serum paraoxonase/ arylesterase polymorphism. Am J Hum Genet 1983;35: 1126-38.
25. Haagen L, Brock A. A new automated method for phenotyping arylesterase (E.C. 3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clim Biochem 1992;30:391-5.
26. Yoshioka T, Kawada K, Shimada T, Mori M. Lipid peroxidation in maternal and cord blood and protective mechanisms against activated oxygen toxicity in the blood. Am J Obster Gynecol 1979;135:372-6.
27. McCord JM, Fridovich I. Superoxide dismutase: an enzymic function for erythrocuprein (hemocuprein). J Biol Chem 1969; 244(22):6049-55.
28. Sonnenwirth AC. Glutathione reductase assay. In: Sonnenwirth AC, Jarett MD, (eds.) Gradwhol's clinical laboratory methods and diagnosis. St. Louis, MO: The CV Mosby Company; 1980;1:854-7.
29. Popov T, Neikovska L. Metod opredeleniia peroksidznoi aktivnosti krovi [Method of determining the peroxidase activity of blood]. Gig Sanit 1971;36(10):89-91.
30. Yang J, Lam EW, Hammad HM, Oberley TD, Oberley LW: Antioxidant enzyme levels in oral squamous cell carcinoma and normal human oral epithelium. J Oral Pathol Med 2002; 31:71-7.
31. Evans MD, Cooke MS. Factors contributing to the outcome of oxidative damage to nucleic acids. Bioessays 2004; 26:533-42.
32. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet 1994;344:721-4.
33. Hayes JD, McLellan LI. Glutathione and glutathione-dependent enzymes represent a coordinately regulated defence against oxidative stress. Free Radic Res 1999;31:273-300.
34. Taysi S, Uslu C, Akcay F, Sutbeyaz MY. Malondialdehyde and nitric oxide levels in the plasma of patients with advanced laryngeal cancer. Surg Today 2003;33:651-4.
35. Dursun H, Bilici M, Uyanik A, Okcu N, Akyuz M. Antioxidant enzyme activities and lipid peroxidation levels in erythrocytes of patients with oesophageal and gastric cancer. J Int Med Res 2006;34(2):193-9.
36. Arivazhagan S, Kavitha K, Nagini S. Erythrocyte lipid peroxidation and antioxidants in gastric cancer patients. Cell Biochem Funct 1997;15:15-8.
37. Bakan E, Taysi S, Polat MF, Dalga S, Umudum Z, Bakan N, et al. Nitric oxide levels and lipid peroxidation in plasma of patients with gastric cancer. Jpn J Clin Oncol 2002;32:162-6.
38. Weber WW. Influence of heredity on human sensitivity to environmental chemicals. Environ Mol Mutagen 1995;25: 102-14.
39. Kerridge I, Lincz L, Scorgie F, Hickey D, Granter N, Spencer A. Association between xenobiotic gene polymorphisms and non-Hodgkin's lymphoma risk. Br J Haematol 2002;118:477-81.
40. Gerber M, Astre C, Segala C, Saintot M, Scali J, Simony-Lafontaine J, et al. Tumor progression and oxidant-antioxidant status. Cancer Lett 1997;114:211-4.
41. Guven M, Ozturk B, Sayal A, Ozeturk A, Ulutin T. Lipid peroxidation and antioxidant system in the blood of cancerous patients with metastasis. Cancer Biochem Biophys 1999;17: 155-62.
42. Skrzydlewska E, Stankiewicz A, Sulkowska M, Sulkowski S, Kasacka I. Antioxidant status and lipid peroxidation in colorectal cancer. J Toxicol Environ Health A 2001;64:213-22.
43. Gutteridge JM. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem 1995;41:1819-28.
44. Sharma A, Rajjapa M, Saxena A, Sharma M. Antioxidant status in advanced cervical cancer patients undergoing neoadjuvant chemoradiation. Br J Biomed Sci 2007;64:23-7.
45. Oberley TD, Oberley LW. Antioxidant enzyme levels in cancer. Histol Histopathol 1997;12:525-35.
46. Kong Q, Beel JA, Lillehei KO. A threshold concept for cancer therapy. Med Hypotheses 2000;55:29-35.
47. Borek C. Dietary antioxidants and human cancer. Integr Cancer Ther 2004;3:333-41.
48. Halliwell B. Effect of diet on cancer development: is oxidative DNA damage a biomarker. Free Radic Biol Med 2002;15: 968-74.
49. Mackness B, Durrington PN, Mackness MI: human serum paraoxonase. Gen Pharmacol 1998;31:329-36.
50. Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase: evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991;19: 100-6.
51. Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic Biol Med 2003;34:774-84.
52. Paglia DE, ValentineWN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967;70:158-69.
53. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999;26:892-904.
54. Antognelli C, Mearini L, Talesa VN, Giannantoni A, Mearini E. Association of CYP 17, GSTPI and PON1 polymorphisms with the risk of prostate cancer. Prostate 2005;63:240-51.
55. Saadat M. Paraoxonase 1 genetic polymorphisms and susceptibility to breast cancer: a meta-analysis. Cancer Epidemiol 2012;36:101-3.
56. Marchesani M, Hakkarainen A, Tuomainen TP, Kaikkonen J, Pukkala E, Uimari P, et al. New paraoxonase1 polymorphism II02V and the risk of prostate cancer in Finnish men. J Natl Cancer Inst 2003;95:812-8.
57. Van Der Logt EM, Janssen CH, Van Hooijdonk Z, Roelofs HM, Wobbes T, Nagengast FM, et al. No association between genetic polymorphisms in NAD(P)H oxidase p22phox and paraoxonase 1 and colorectal cancer risk. Anticancer Res 2005;25:1465-70.
58. Vecka M, Jáchymová M, Vávrová L, Kodydková J, Macášek J, Urbánek M, et al. Paraoxonase-1 (PON1) status in pancreatic cancer: relation to clinical parameters. Folia Biol (Praha) 2012; 58(6):231-7.